#132 – AMA #16: Exploring hot and cold therapy
“All of the work that went into this analysis earlier in the year, it really changed my tune. And I think I’m now at the point where I kind of want to have a sauna, frankly, in the tool kit for longevity.” — Peter Attia
#103 – Looking back on the first 99 episodes: Strong Convictions, Loosely Held
“I reserve metformin prescriptions for patients who obviously are in need of it from the standpoint of glucose and insulin regulation, but I don’t view it really as a pro longevity agent yet.” — Peter Attia
#81 – Debra Kimless, M.D. & Steve Goldner, J.D.: Cannabis – the latest science on CBD & THC
“Cannabis is a gateway more towards health than to other drugs.” —Steve Goldner
Qualy #61 – Rapamycin in cancer treatment
Today’s episode of The Qualys is from podcast #10 – Matt Kaeberlein, Ph.D.: rapamycin and dogs — man’s best friends?…
Qualy #52 – Insights about berberine
Today’s episode of The Qualys is from podcast #26 – AMA #3: supplements, women’s health, patient care, and more.
Qualy #46 – Rapamycin’s effects on cancer, cardiovascular disease, and neurodegeneration
Today’s episode of The Qualys is from podcast #09 – David Sabatini, M.D., Ph.D.: rapamycin and the discovery of mTOR…
#75 – David Light: Zantac recall due to cancer concerns – what you need to know
“We have to come to grasp the reality that there are problems in the medication system in generics, potentially even brand, and all sorts of holes that exist in how the system is now for medications. We want to be a part of that solution and work together to ensure that every patient is getting a high quality medication.” — David Light
Metformin and exercise – déjà vu all over again?
Metformin blunts muscle hypertrophy in response to progressive resistance training
Hormone therapy and breast cancer?
There are not many topics in clinical medicine more polarizing than hormone replacement therapy (HRT) for women suffering from menopausal…
#71 – Katherine Eban: Widespread fraud in the generic drug industry
“Generics are supposed to be this great leveler. It’s like the democratization of drugs that the rich and the poor alike can have access to for these great cures. To find out…that the companies cashing in on that image are really selling that short in a very devious way, is painful to realize. It’s a real great public health hope that has a very dark underbelly.” — Katherine Eban